Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma's Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone (Businesswire) - Sep 3, 2024 - "Tris Pharma, Inc...announced that data from a clinical study of cebranopadol suggest the investigational pain therapy produces potent and prolonged analgesia with 25% less respiratory depression than oxycodone....The findings will be shared in a poster presentation on September 4, 2024, at the 2024 PAINWeek conference in Las Vegas....At equianalgesic doses, cebranopadol produces 25% less respiratory depression compared to oxycodone. Treatment with cebranopadol presents a significantly longer time to impact on respiratory parameters compared to oxycodone, allowing for the gradual accumulation of arterial CO2 and mitigating the full manifestation of respiratory depression. Cebranopadol achieved prolonged analgesic effects with gradual onset and offset."
Clinical data • Back Pain • Immunology • Pain
|